
    
      Protocol Number: SP11631 Study Stage: Phase III Study Population Female patients with breast
      cancer will be enrolled to receive at least 4 cycles of EC chemotherapy, that is: epirubicin
      100 mg/m2 and cyclophosphamide 600 mg/m2.

      Study Design: A multi-center, randomized, open-label, active-controlled phase III clinical
      trial Site Number: 14 sites(planned) , 12 sites(actual) Subject Number: 240
    
  